Historical Valuation
Xilio Therapeutics Inc (XLO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.35 is considered Undervalued compared with the five-year average of -1.38. The fair price of Xilio Therapeutics Inc (XLO) is between 1.03 to 1.58 according to relative valuation methord. Compared to the current price of 0.71 USD , Xilio Therapeutics Inc is Undervalued By 30.8%.
Relative Value
Fair Zone
1.03-1.58
Current Price：0.71
30.8%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Xilio Therapeutics Inc (XLO) has a current Price-to-Book (P/B) ratio of -4.30. Compared to its 3-year average P/B ratio of 1.14 , the current P/B ratio is approximately -477.94% higher. Relative to its 5-year average P/B ratio of 1.01, the current P/B ratio is about -527.10% higher. Xilio Therapeutics Inc (XLO) has a Forward Free Cash Flow (FCF) yield of approximately -49.85%. Compared to its 3-year average FCF yield of -103.06%, the current FCF yield is approximately -51.63% lower. Relative to its 5-year average FCF yield of -94.62% , the current FCF yield is about -47.31% lower.
P/B
Median3y
1.14
Median5y
1.01
FCF Yield
Median3y
-103.06
Median5y
-94.62
Competitors Valuation Multiple
AI Analysis for XLO
The average P/S ratio for XLO competitors is 5.93, providing a benchmark for relative valuation. Xilio Therapeutics Inc Corp (XLO.O) exhibits a P/S ratio of 1.35, which is -77.2% above the industry average. Given its robust revenue growth of 742.51%, this premium appears sustainable.
Performance Decomposition
AI Analysis for XLO
1Y
3Y
5Y
Market capitalization of XLO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of XLO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is XLO currently overvalued or undervalued?
Xilio Therapeutics Inc (XLO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.35 is considered Undervalued compared with the five-year average of -1.38. The fair price of Xilio Therapeutics Inc (XLO) is between 1.03 to 1.58 according to relative valuation methord. Compared to the current price of 0.71 USD , Xilio Therapeutics Inc is Undervalued By 30.80% .
What is Xilio Therapeutics Inc (XLO) fair value?
XLO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Xilio Therapeutics Inc (XLO) is between 1.03 to 1.58 according to relative valuation methord.
How does XLO's valuation metrics compare to the industry average?
The average P/S ratio for XLO's competitors is 5.93, providing a benchmark for relative valuation. Xilio Therapeutics Inc Corp (XLO) exhibits a P/S ratio of 1.35, which is -77.20% above the industry average. Given its robust revenue growth of 742.51%, this premium appears sustainable.
What is the current P/B ratio for Xilio Therapeutics Inc (XLO) as of Jan 09 2026?
As of Jan 09 2026, Xilio Therapeutics Inc (XLO) has a P/B ratio of -4.30. This indicates that the market values XLO at -4.30 times its book value.
What is the current FCF Yield for Xilio Therapeutics Inc (XLO) as of Jan 09 2026?
As of Jan 09 2026, Xilio Therapeutics Inc (XLO) has a FCF Yield of -49.85%. This means that for every dollar of Xilio Therapeutics Inc’s market capitalization, the company generates -49.85 cents in free cash flow.
What is the current Forward P/E ratio for Xilio Therapeutics Inc (XLO) as of Jan 09 2026?
As of Jan 09 2026, Xilio Therapeutics Inc (XLO) has a Forward P/E ratio of -1.22. This means the market is willing to pay $-1.22 for every dollar of Xilio Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Xilio Therapeutics Inc (XLO) as of Jan 09 2026?
As of Jan 09 2026, Xilio Therapeutics Inc (XLO) has a Forward P/S ratio of 1.35. This means the market is valuing XLO at $1.35 for every dollar of expected revenue over the next 12 months.